Specialty
Aesthetics Cataract & Refractive Dermatology General Ophthalmology Glaucoma Interventional Radiology Neurology Optometry Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Search
Log In

Co-Managing the Diabetic Patient

By: Mark Dunbar, OD, Moderator; Paul Chous, OD; Leo Semes, OD

This course has expired. You can still review the content but course credit is no longer available.

Webinar Credits: 1

Diabetes is a growing epidemic in the United States, and diabetic macular edema (DME) and diabetic retinopathy (DR) poses a substantial risk for vision loss if not diagnosed and/or treated. It remains clear that although diabetes is a systemic disorder, the manifestations of diabetic complications will occur without optimal glycemic and blood pressure control. Optometrists can help continually reinforce that message by educating patients about the necessity for ongoing and yearly dilated eye exams, and discussing the potential treatments should vision loss become obvious.

Expiration Date: Friday, June 30, 2017
Release Date: June 21, 2016

Learning Objectives

Target Audience
This activity intends to educate optometrists.

Learning Objectives
Upon completion of this activity, participants should be better able to:

  • Determine who is a high-risk patient for the onset of diabetic eye disease
  • Discuss the importance of conducting yearly dilated exams on diabetic patients
  • Develop plans to initiate co-management of the diabetic patient with both ophthalmologists and primary care physicians/endocrinologists
  • Implement strategies to educate patients on the ocular manifestations of diabetes

Accreditation and Designation Statement

This course is COPE approved for 1.0 hour of CE credit for optometrists.

COPE Course ID: 49883-SD

COPE Event ID: 111606

Faculty and Disclosures

Mark Dunbar, OD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Allergan, Inc.; Carl Zeiss Meditec and Regeneron Pharmaceuticals, Inc.

Paul Chous, OD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Bausch & Lomb Incorporated; CooperVision; Freedom Meditech, Inc.; Regeneron Pharmaceuticals, Inc.; and ZeaVision, LLC and Grant/Research Support: ZeaVision, LLC

Leo Semes, OD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; Allergan, Inc.; Optovue, Inc.; and Regeneron Pharmaceuticals, Inc. and Stock/Shareholder: HPO

Cheryl Cavanaugh, MS; Michelle Dalton and Melanie Lawler, PhD have no relevant commercial interests to disclose.

Disclosure Attestation
Each of the contributing faculty listed above has attested to the following:

1.       That the relationships/affiliations noted will not bias or otherwise influence his or her involvement in this activity;

2.       That practice recommendations given relevant to the companies with whom he or she has relationships/affiliations will be supported by the best available evidence or, absent evidence, will be consistent with generally accepted medical practice; and

3.       That all reasonable clinical alternatives will be discussed when making practice recommendations.

Disclaimer

Off Label Disclosure

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Co-Managing the Diabetic Patient

Mark Dunbar, OD, Moderator; Paul Chous, OD; Leo Semes, OD

BackNext